To view the full article click here.

Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE),  tells Proactive they’ve been given the green light from US authorities to kick off a phase IIb study of its CTX cell therapy candidate for stroke disability.

Long-term data from the PISCES II trial earlier this year showed the treatment has the potential to improve the disability of stroke patients.

PISCES III – as this next study will be called – will be much bigger, recruiting 110 patients across 25 sites in the US.

The approval caps off a productive six months for the cell-based therapeutics specialist, during which it also started dosing patients in the phase II element of the ongoing phase I/II clinical trial of its hRPC stem cell therapy candidate for retinitis pigmentosa